Lilly plays up Cyramza's biomarker edge in crowded liver cancer field

KYLE BLANKENSHIP | May 13, 2019 | 228 views

It’s been a long road for Eli Lilly’s Cyramza in liver cancer after it belly-flopped a phase 3 trial five years ago. On the back of a successful second attempt, the drugmaker has finally accomplished what once seemed out of reach—but these days, there's a lot more competition in the field than there used to be. Monday, the FDA approved Cyramza for the treatment of liver cancer patients who have failed on Bayer's Nexavar, and in that field, it'll go up against a range of big-name rivals. But unlike those rivals, Cyramza has a targeted green light, clearing it specifically to treat patients with high levels of the glycoprotein alpha-fetoprotein (AFP), a biomarker that can lead to worse outcomes. It affects about 40% of patients with hepatocellular carcinoma, the most common form of liver cancer, Lilly said.

Spotlight

Nuventra Pharma Sciences

Nuventra is the pharmaceutical industry’s go-to resource for clinical pharmacology, pharmacokinetic, and pharmacometric consulting services.

OTHER ARTICLES
PHARMA TECH

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | July 13, 2022

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More
PHARMA TECH

What are the advantages of PCD Pharma Company?

Article | September 29, 2022

PCD Pharma stands for propaganda distribution. A PCD company gives brand name and support to its franchises. They also provide distribution rights and monopoly rights within a particular region. If a person wants to establish their business, it is a must for them to know the pros and cons of the business to make a sound decision. Needless to mention that PCD company has a lot to contribute in the medical filed. Worldwide in a medical field, A PCD Pharma Company is playing an essential and crucial role in the rapid growth. The pharma industry is progressing t a fast pace. The company uses the latest technologies for each brand which ensures the safety of products and accepts the responsibility of human health & life by providing better outcomes. To have a drug license number and company registration, the cost to establish the company is quite cost-effective that is15000-20000rs. So this gives people a brilliant opportunity to have their unit without digging a big hole in their bank balance. Indian produces exquisite quality products, which make pharma companies a considerable success.

Read More
PHARMA TECH

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | July 12, 2022

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

How Can Medical Cannabis Help to Manage Pain Conditions? – The Cannabis Exchange

Article | February 11, 2020

Pain management is one of the most common reasons for the use of medical cannabis products. However, despite many jurisdictions – including Canada, Germany, and the Netherlands – now allowing the prescription of medical cannabis for this purpose, there remains little ‘high-quality’ evidence to support, or oppose its efficacy. Madden et al. (2018) set out to review the evidence available in order to determine the efficacy of medical cannabis when employed in the management of various forms of musculoskeletal pain. The researchers analysed various studies that assessed the use of cannabinoids in the treatment of arthritis pain; back pain; postoperative pain; and trauma-related pain. It is estimated that up to 30% of the population may suffer from a non-cancer-related pain condition. As such a high percentage of people suffer from these conditions, the development of simple and safe therapies is an essential area of research. This is particularly important as the therapeutic options for people with chronic pain are increasingly limited.

Read More

Spotlight

Nuventra Pharma Sciences

Nuventra is the pharmaceutical industry’s go-to resource for clinical pharmacology, pharmacokinetic, and pharmacometric consulting services.

Related News

Lilly to invest $400m to boost manufacturing capacity in US

Pharmaceutical Technology | November 21, 2019

Eli Lilly is set to invest $400m to boost the capacity of its manufacturing facilities at its technology centre campus in Indianapolis, Indiana, US. The move is intended to meet the increasing demand for the company’s existing medicines and to support the production of future drugs in its pipeline. Lilly will use the capital to add enhancements to facilities that manufacture insulin, boost capacity for its diabetes portfolio and as initial capital for future drugs. Furthermore, the company expects the investment to create nearly 100 jobs in manufacturing. Eli Lilly chairman and CEO David Ricks said: “These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the US and have been made possible by the tax reform measures passed by Congress in 2017. “With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home.” The investment will bring capacity and technology upgrades to the company’s active ingredient, syringe filling, device assembly and packaging operations.

Read More

Lilly's Taltz scrapes win against Humira in psoriatic arthritis

Pharmaphorum | June 14, 2019

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just. Lilly reported last year that the SPIRIT-H2H trial had shown Taltz (ixekizumab) met its primary endpoint of superiority to Humira (adalimumab) as measured by the proportion of patients who saw their disease activity cut by 50% as well as complete skin clearance, without providing the data. At the Annual European Congress of Rheumatology (EULAR) in Madrid it has now revealed that the proportion of patients who achieved the primary endpoint at 24 weeks was 36% with Taltz and 28% with Humira, which just met the threshold for statistical significance with a P value of less than <0.05. Breaking down the results, the IL-17 inhibitor was found to be around the same as Humira on the 50% improvement in disease activity (ACR50) score – at 51% versus 47% with AbbVie’s drug – and had a stronger impact on the skin clearance (PASI 100) measure (60% versus 47%) with a P value of 0.001. The results of the open-label phase 3b/4 trial show that most of the benefit over Humira appears to come from resolving the skin symptoms of psoriatic arthritis, an indication for which Taltz was approved in 2017 after getting the go-ahead initially in plaque psoriasis in 2016.

Read More

Lilly to invest $400m to boost manufacturing capacity in US

Pharmaceutical Technology | November 21, 2019

Eli Lilly is set to invest $400m to boost the capacity of its manufacturing facilities at its technology centre campus in Indianapolis, Indiana, US. The move is intended to meet the increasing demand for the company’s existing medicines and to support the production of future drugs in its pipeline. Lilly will use the capital to add enhancements to facilities that manufacture insulin, boost capacity for its diabetes portfolio and as initial capital for future drugs. Furthermore, the company expects the investment to create nearly 100 jobs in manufacturing. Eli Lilly chairman and CEO David Ricks said: “These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the US and have been made possible by the tax reform measures passed by Congress in 2017. “With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home.” The investment will bring capacity and technology upgrades to the company’s active ingredient, syringe filling, device assembly and packaging operations.

Read More

Lilly's Taltz scrapes win against Humira in psoriatic arthritis

Pharmaphorum | June 14, 2019

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been treated before with a disease-modifying drug, but only just. Lilly reported last year that the SPIRIT-H2H trial had shown Taltz (ixekizumab) met its primary endpoint of superiority to Humira (adalimumab) as measured by the proportion of patients who saw their disease activity cut by 50% as well as complete skin clearance, without providing the data. At the Annual European Congress of Rheumatology (EULAR) in Madrid it has now revealed that the proportion of patients who achieved the primary endpoint at 24 weeks was 36% with Taltz and 28% with Humira, which just met the threshold for statistical significance with a P value of less than <0.05. Breaking down the results, the IL-17 inhibitor was found to be around the same as Humira on the 50% improvement in disease activity (ACR50) score – at 51% versus 47% with AbbVie’s drug – and had a stronger impact on the skin clearance (PASI 100) measure (60% versus 47%) with a P value of 0.001. The results of the open-label phase 3b/4 trial show that most of the benefit over Humira appears to come from resolving the skin symptoms of psoriatic arthritis, an indication for which Taltz was approved in 2017 after getting the go-ahead initially in plaque psoriasis in 2016.

Read More

Events